Best-practice Interventions Research Articles

Perianal disease remains an understudied and difficult complication in leukemia patients.

e19016 Background: Perianal infection is a rare and poorly understood complication of patients with acute myeloid/lymphocytic leukemia (AML/ALL). With the advancements in oncology, patients are living longer in an immunocompromised state and thus bearing the inherent problems such as infections that arise with it. Perianal infection and its management impacts patients' quality of life as well as interrupts their ongoing oncologic treatment. The optimal treatment strategy for perianal infections in this highly immunocompromised group remains unclear, as does the selection and outcomes of patients for operative intervention. The aim of this study is to identify patient characteristics associated with perianal infection and to delineate outcomes in patients that undergo operative intervention. Methods: The National Inpatient Sample (NIS) database was used to identify hospitalized patients with diagnoses of perianal abscess and AML/ALL between 2007 and 2015. Patient data were weighted to obtain national estimates. Demographics and clinical characteristics were compared between patients with and without perianal disease using Rao-Scott Chi-square test for categorical variables, and weighted simple linear regression for continuous variables. Characteristics and outcomes were compared between patients who underwent operative or non-operative management. Results: There were 12,626 (0.7%) patients with perianal disease among 1,782,778 AML/ALL patient admissions. Patients with perianal disease were more likely to be younger (43.9 (42.5 – 45.3) years, p < 0.001), male (67.4% vs 32.6%, p < 0.001) and white (65.8% vs 54.8%, p < 0.001). Length of stay (18.4 days vs 9 days, p < 0.001) and hospital cost ($54K vs $25K, p < 0.001) were higher in those with perianal disease, but there was no difference in in-hospital mortality (5.5% in those with perianal diseases vs 6.2% in those without, p = 0.150). Greater proportion of patients without perianal disease were discharged to hospice (12.6% patients without perianal disease vs 5.1% patients with perianal disease, p < 0.001). Receiving a surgical intervention did not improve outcomes with respect to in-hospital mortality (5.9% operative vs 5.4 non-operative, p = 0.596), length of stay (20.2 days vs 18.2 days, p = 0.582) or hospital cost ($67K vs $53K, p = 0.525). Conclusions: Perianal disease is a rare but distressing complication in AML/ALL patients associated with longer hospital stays and higher hospital costs. Operative intervention for perianal disease did not reduce rates of in-hospital mortality, length of stay or hospital cost but it does impact the probability of discharge to hospice. Non-operative and operative intervention both remain equivocal in changing the outcomes these patients. Further studies are required to examine these associations and determine best practices for treatment of this condition in this complex patient population.

Understanding psychological treatment barriers, preferences and histories of individuals with clinically significant depressive symptoms in Australia: a preliminary study

ABSTRACT Objective: Depressive symptoms are common, yet many individuals in Australia do not seek treatment. The aim of this study was to explore 1) psychological treatment barriers, 2) psychological treatment delivery preferences, 3) predictors of psychological help-seeking intention, and 4) treatment histories of individuals with clinically significant depressive symptoms in Australia. Method: One hundred and eighty-two individuals (Mage = 36.77, SD = 11.94; range 18-73; 92.3% female) were included in the study. Data was collected online from a community sample of individuals with clinically significant depressive symptoms. Results: The most frequently endorsed barrier to seeking psychological treatment was cost (66.5%). Participants generally preferred standard face-to-face treatment (58.8%). Participant age, number of barriers, depression severity and self-stigma explained 32% of the variance in future psychological help-seeking intention. Sixty-one percent of participants indicated receiving cognitive-behaviour therapy in the past, but less than one in five received a likely best-practice treatment according to expert consensus guidelines. Conclusions: Many Australians require more cost-effective treatments, as well as treatments using remote delivery approaches. Funders may need to assess fidelity to evidence-based interventions. Key Points (1) Cost is a significant barrier to accessing treatment for individuals with depressive symptoms. (2) Patients with depressive symptoms prefer face-to-face treatment over other treatment approaches. (3)Less than one in five patients receives best-practice treatment for their depressive symptoms.

Sinonasal Renal Cell-Like Adenocarcinoma

Sinonasal renal cell-like adenocarcinoma (SNRCLA) is a newly defined, rare malignant tumor of the nasal cavity. The clinical course and response to treatment remain uncertain. The purpose of this study is to report a new case of SNRCLA and review the literature to determine clinical characteristics, treatment options, and outcomes. A 26-year-old male presented with headache, epistaxis, and nasal obstruction. Physical examination revealed a tumor involving bilateral ethmoid sinuses and MRI revealed extension through the cribriform plate. Surgical excision with endonasal and a bifrontal craniotomy was performed followed by adjuvant radiotherapy (RT). After RT, the patient had persistent disease requiring salvage surgery.There are few previously reported cases of SNRCLA. A literature review yielded 14 previously reported cases with convincing diagnostic evidence of SNRCLA. Common presenting symptoms were epistaxis and nasal obstruction. Surgical excision was the primary treatment in fourteen cases, nine received RT, and none received chemotherapy. However, three cases had persistent or recurrent disease. Surgical excision is the mainstay of treatment for SNRCLA and adjuvant RT has been used in some patients with varying outcomes. The tumor is low grade with no reported cases of metastases or death. The best practice for treatment is yet to be determined.

Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).

Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).

A system for 3D reconstruction of comminuted tibial plafond bone fractures.

High energy impacts at joint locations often generate highly fragmented, or comminuted, bone fractures. Current approaches for treatment require physicians to decide how to classify the fracture within a hierarchy fracture severity categories. Each category then provides a best-practice treatment scenario to obtain the best possible prognosis for the patient. This article identifies shortcomings associated with qualitative-only evaluation of fracture severity and provides new quantitative metrics that serve to address these shortcomings. We propose a system to semi-automatically extract quantitative metrics that are major indicators of fracture severity. These include: (i) fracture surface area, i.e., how much surface area was generated when the bone broke apart, and (ii) dispersion, i.e., how far the fragments have rotated and translated from their original anatomic positions. This article describes new computational tools to extract these metrics by computationally reconstructing 3D bone anatomy from CT images with a focus on tibial plafond fracture cases where difficult qualitative fracture severity cases are more prevalent. Reconstruction is accomplished within a single system that integrates several novel algorithms that identify, extract and piece-together fractured fragments in a virtual environment. Doing so provides objective quantitative measures for these fracture severity indicators. The availability of such measures provides new tools for fracture severity assessment which may lead to improved fracture treatment. This paper describes the system, the underlying algorithms and the metrics of the reconstruction results by quantitatively analyzing six clinical tibial plafond fracture cases.

Imaging Identification and Prognosis of the Distal Internal Carotid Artery With Near and Complete Occlusion After Recanalization.

Background and Purpose: Previous studies have mainly focused on treatment strategies and clinical outcomes for internal carotid artery near occlusion (ICANO) and internal carotid artery complete occlusion (ICACO). However, reports on the morphological changes of distal internal carotid artery (ICA) after recanalization are scarce. This study aimed at illustrating identifying features, assessing prognosis of the distal ICA after recanalization, and exploring best practices for treatment for ICANO and ICACO.Materials and Methods: We retrospectively studied the clinical characteristics of 57 patients with ICANO or ICACO who underwent surgical recanalization. The clinical data, angiographic morphology, technical successful rate, perioperative complications, and the lumen changes of distal ICA before and after successful recanalization were analyzed.Results: Fifty-two patients who achieved successfully recanalization were studied. Based on the postoperative lumen diameter changes in the distal ICA, 19 cases were classified as distal-dilatation and the remaining 33 as distal-narrowness. Patients in the distal-narrowness group mostly had ICACO (21.1 vs. 54.5%) and were men (68.4 vs. 93.9%). In the distal-narrowness group, the lumen of the distal ICA recovered to normal in 32 of the 33 patients during the follow-up period. Of the 32 patients reviewed, the ICA of 28 patients dilated back to normal after 1 week of surgery; the ICA of remaining patients 4 dilated 2 weeks postoperatively.Conclusions: Narrowness of the distal ICA after hybrid recanalization was more prevalent in male patients with ICACO. Homogeneous stenosis of the whole course of the distal ICA is a low-perfusion narrowness which does not require intervention and will spontaneously recover after successful recanalization with an increase in the forward flow.

Early intervention for children with/at risk of developmental coordination disorder: a scoping review.

To summarize current evidence for early identification and motor-based intervention for children aged 5 years and younger of age with/at risk of developmental coordination disorder (DCD). Using scoping review methodology, we independently screened over 11 000 articles and selected those that met inclusion criteria. Of the 103 included articles, 78 articles were related to early identification and are summarized in a companion article. Twenty-two articles focused on early intervention, with an additional three articles covering both early identification and intervention. Most intervention studies were at a low level of evidence, but provide encouraging evidence that early intervention is beneficial for young children with/at risk of DCD. Direct intervention can be provided to whole classes, small groups, or individuals according to a tiers of service delivery model. Educating and building the capacity of parents and early childhood educators are also key elements of early intervention. Evidence for early intervention for children with/at risk of DCD is emerging with promising results. Further studies are needed to determine best practice for early intervention and whether intervening early can prevent the negative developmental trajectory and secondary psychosocial consequences associated with DCD.

The application of a new laminitis scoring method to model the rate and pattern of improvement from equine endocrinopathic laminitis in a clinical setting

BackgroundEndocrinopathic, or hyperinsulinaemia-associated laminitis (HAL) is a common and debilitating equine foot disease, and although no pharmacological treatments are registered, several are under development. To evaluate the effect of such treatments, an accurate and consistent method is needed to track the clinical signs of laminitis over time, and the natural history of the disease, in terms of a ‘normal’ pattern of improvement, needs to be understood. This study examined the improvement pattern in clinical cases of naturally-occurring HAL subjected to a range of best-practice interventions, using two different scoring methods. Eighty horses and ponies with suspected HAL were enrolled in a study conducted at 16 veterinary practices across Germany. The severity of laminitis was assessed by independent veterinarians using both the traditional Obel method and a modified Obel method developed by Meier and colleagues. Assessments were made on the day of diagnosis (d 0), then on days 4, 9, 14, 25 and 42 during the intervention period. Pain medications were withheld for 24 h prior to clinical examination in all cases.ResultsTime to marked improvement from laminitis varied between individuals, but was difficult to monitor accurately using the Obel method, with the median grade being 2/4 on days 0 and 4, then 0/4 from d 9 onwards. More subtle changes could be identified using the Meier method, however, and the median scores were seen to follow the form of an exponential decay model in most horses, improving from 8/12 on d 0, to 0/12 on d 25. Within this composite scoring method, considerable variation was observed in the rate of improvement of individual clinical signs, with the average time taken for each sign to reach a median score of 0 ranging from 4 days (foot lift and weight shifting) to 25 days (gait when turned in a circle) across all 80 horses.ConclusionsThe Meier method provides a reliable and consistent method for monitoring the clinical status of horses with HAL, and despite the variability, the pattern of improvement described here should provide a useful benchmark against which individual cases and new treatments can be assessed.

Speech and Anxiety Management With Persistent Stuttering: Current Status and Essential Research.

Purpose The purpose of this review article is to provide an overview of the current evidence base for the behavioral management of stuttering and associated social anxiety. Method We overview recent research about stuttering and social anxiety in the context of contemporary cognitive models of social anxiety disorder. That emerging evidence for self-focused attention and safety behavior use with those who stutter is considered in relation to current treatment approaches for stuttering: speech restructuring and social anxiety management. Results The emerging information about social anxiety and stuttering suggests a conflict between the two clinical approaches. For those clients who wish to control their stuttering and where speech restructuring is deemed the most suitable approach, it is possible that speech restructuring may (a) induce or increase self-focused attention, (b) promote the use of safety behaviors, and (c) become a safety behavior itself. This conflict needs to be explored further within clinical and research contexts. Conclusions The issues raised in this review article are complex. It appears that evidence-based speech treatment procedures are in conflict with current best-practice treatment procedures that deal with social anxiety. In this review article, we propose directions for future research to inform the development of improved treatments for those who stutter and recommendations for interim clinical management of stuttering.

Priority Setting in HIV, Tuberculosis, and Malaria - New Cost-Effectiveness Results From WHO-CHOICE.

Background: This paper forms part of an update of the World Health Organization Choosing Interventions that are Cost-Effective (WHO-CHOICE) programmes. It provides an assessment of global health system performance during the first decade of the 21st century (2000-2010) with respect to allocative efficiency in HIV, tuberculosis (TB) and malaria control, thereby shining a spotlight on programme development and scale up in these Millennium Development Goal (MDG) priority areas; and examining the cost-effectiveness of selected best-practice interventions and intervention packages commonly in use during that period. Methods: Generalized cost-effectiveness analysis (GCEA) was used to determine the cost-effectiveness of the selected interventions. Impact modelling was performed using the OpenMalaria platform for malaria and using the Goals and TIME (TB Impact Model and Estimates) models in Spectrum for HIV and TB. All health system costs, regardless of payer, were included and reported in international dollars. Health outcomes are estimated and reported as the gain in healthy life years (HLYs) due to the specific intervention or combination. Analysis was restricted to eastern sub-Saharan Africa and Southeast Asia. Results: At the reference year of 2010, commonly used interventions for HIV, TB and malaria were cost-effective, with cost-effectiveness ratios less than I$ 100/HLY saved for virtually all interventions included. HIV, TB and malaria prevention and treatment interventions are highly cost-effective and can be implemented through a phased approach to full coverage to achieve maximum health benefits and contribute to the progressive elimination of these diseases. Conclusion: During the first decade of the 21st century (2000-2010), the global community has done well overall for HIV, TB, and malaria programmes as regards both economic efficiency and programmatic selection criteria. The role of international assistance, financial and technical, arguably was critical to these successes. As the global community now tackles the challenge of universal health coverage, this analysis can reinforce commitment to Sustainable Development Goal targets but also the importance of continued focus on these critical programme areas.

The circularity of potential bio-textile production routes: Comparing life cycle impacts of bio-based materials used within the manufacturing of selected leather substitutes

Nowadays the fashion industry faces increasing pressures to reduce the environmental impacts associated to the production of leather-based fashion products, particularly considering issues regarding public acceptance due to animal welfare standards and due to the toxicity of tanning chemicals. An alternative solution facilitated by the bio-textiles industry is the introduction of vegan and bio-based leather substitutes for the production of shoes, handbags, clothing’s and upholstery i.e. on the basis of natural fibres, bio-based polymers, microbial cellulose and fungal mycelium composite products. Nonetheless, also these bio-based leather products cause negative environmental impacts i.e. related to land-use change and intensification, to water use and to energy use in polymer manufacturing. For further impact reduction and designing environmentally most sound solutions, design of leather substitute products should integrate best-practice interventions for increased circularity along the full product life cycles from fibre feedstock provisioning to polymer production and end-of-life recyclability and degradability. This study evaluated the current best practice scenarios for impact reduction when implementing circular design strategies in the production of bio-based fashion materials. Three case studies of alternative leather substitutes were considered, including respectively two sub-scenarios in a comparative Life Cycle Impact Assessment. Results for the aggregated single score using the Environmental footprint approach showed that principles of circularity (e.g. the feedstock type and by-product recovery for fiber and sugar feedstocks) have an influence of 65% between the best and worst performer in mitigating environmental impacts. Furthermore, enhancing the product durability of the leather substitutes against the temporal product replacement benchmark of animal leather would have an influence of 25–70% in mitigating impacts concerning water scarcity and climate change. The most important conclusion of this work is that alternative leather substitutes can contribute to relative environmental advantages in impact reduction in 8–14 impact categories, but only as long as the material substitution is coupled with less frequent product replacement and preferably also low impact coating systems and impregnation agents.

Precision population analytics: population management at the point-of-care

ObjectiveTo present clinicians at the point-of-care with real-world data on the effectiveness of various treatment options in a precision cohort of patients closely matched to the index patient.Materials and MethodsWe developed disease-specific, machine-learning, patient-similarity models for hypertension (HTN), type II diabetes mellitus (T2DM), and hyperlipidemia (HL) using data on approximately 2.5 million patients in a large medical group practice. For each identified decision point, an encounter during which the patient’s condition was not controlled, we compared the actual outcome of the treatment decision administered to that of the best-achieved outcome for similar patients in similar clinical situations.ResultsFor the majority of decision points (66.8%, 59.0%, and 83.5% for HTN, T2DM, and HL, respectively), there were alternative treatment options administered to patients in the precision cohort that resulted in a significantly increased proportion of patients under control than the treatment option chosen for the index patient. The expected percentage of patients whose condition would have been controlled if the best-practice treatment option had been chosen would have been better than the actual percentage by: 36% (65.1% vs 48.0%, HTN), 68% (37.7% vs 22.5%, T2DM), and 138% (75.3% vs 31.7%, HL).ConclusionClinical guidelines are primarily based on the results of randomized controlled trials, which apply to a homogeneous subject population. Providing the effectiveness of various treatment options used in a precision cohort of patients similar to the index patient can provide complementary information to tailor guideline recommendations for individual patients and potentially improve outcomes.

Responsible use of medicines and medicine recording

In his presentation at the UK-Vet Healthy Herd 2020 Digital Event on 21st October 2020 Professor Barrett spoke to a mixed audience of both farmers and veterinary surgeons. His talk on the ‘Responsible use of medicines and medicine recording’ in livestock, explained the key factors that influence best-practice treatment decisions within the context of legislation, quality assurance and market demand.

Vicarious learning in the time of coronavirus

Health professionals confronting the COVID-19 pandemic need to learn vicariously—that is, learn the lessons of others’ experiences—if they are to adopt and spread best practices for treatment, avoid costly repetition of prior mistakes, and not waste time “reinventing the wheel.” Digital communication tools and social media could be leveraged to facilitate this vicarious learning in much the same way that they are being used to support other types of interpersonal interactions amid social distancing. Yet these tools are often not used to their full potential for learning and knowledge sharing among health professionals fighting COVID-19. Drawing on organizational and behavioral science research into how individuals and organizations learn from others’ experiences, I recommend guidelines, policies, and practices that can increase both the use and the effectiveness of technological tools and social media to enhance vicarious learning among the health professionals at the front lines of pandemic care.

Generating psychotherapy breakthroughs: Transtheoretical strategies from population health psychology.

Over the past 40 years, few breakthroughs have dramatically increased the impacts of psychotherapy. There have been new and exciting therapies, but the research does not convincingly demonstrate that any recent or more established therapies produce greater impacts than 40 years ago. Seven strategies from the transtheoretical model that have produced breakthroughs in health psychology/population health are analyzed to illustrate how they can similarly generate breakthroughs in mental health outcomes. The first three strategies can enhance impacts by increasing the percentage of troubled populations entering and completing best-practice treatments: reach, recruit, and retain. The fourth strategy accords higher value to synergy than to specificity by generating more benefits from whole-health therapies that briefly treat the small number of behaviors that account for a large percentage of chronic disabilities and premature deaths. The fifth breakthrough strategy creates multiple synergistic changes within individuals; changing one problem behavior promotes the probabilities that individuals will change a second problem (coaction). The sixth strategy increases impacts by complementing psychologists with tailored technology that extends their influence into homes, schools, workplaces, and communities. The seventh strategy calls on researchers to test their innovations against best practices and to benchmark outcomes, like those found with depression. We conclude by advancing a framework that can generate more inclusive and effective psychotherapies by integrating individual health care with population health practices. (PsycInfo Database Record (c) 2020 APA, all rights reserved).

Psychologists' Role in Concussion Assessments for Children and Adolescents in Pediatric Practice.

An estimated 1.1 to 1.9 million children and adolescents in the United States are treated for a sports- or recreationally-related concussion each year. The importance of formalized assessment and measurement of concussion symptoms has been widely recognized as a component of best-practice treatment. The present paper reviews a sample of the most commonly used measures of concussion symptomology and explores psychologists’ role in their application in a pediatric practice. In addition, other issues such as accessibility and the appropriateness of application with child and adolescent patients are discussed. Literature is reviewed from journals pertaining to pediatric and adolescent medicine, sports medicine, neuropsychology, and testing and measurement.

Emergency Medical Service Directors' Protocols for Exertional Heat Stroke.

Background and Objectives: Emergency Medical Service (EMS) protocols vary widely and may not implement best practices for exertional heat stroke (EHS). EHS is 100% survivable if best practices are implemented within 30 min. The purpose of this study is to compare EMS protocols to best practices for recognizing and treating EHS. Materials and Methods: Individuals (n = 1350) serving as EMS Medical or Physician Director were invited to complete a survey. The questions related to the EHS protocols for their EMS service. 145 individuals completed the survey (response rate = 10.74%). Chi-Squared Tests of Associations (χ2) with 95% confidence intervals (CI) were calculated. Prevalence ratios (PR) with 95% CI were calculated to determine the prevalence of implementing best practices based on location, working with an athletic trainer, number of EHS cases, and years of directing. All PRs whose 95% CIs excluded 1.00 were considered statistically significant; Chi-Squared values with p values < 0.05 were considered statistically significant. Results: A majority of the respondents reported not using rectal thermometry for the diagnosis of EHS (n = 102, 77.93%) and not using cold water immersion for the treatment of EHS (n = 102, 70.34%). If working with an athletic trainer, EMS is more likely to implement best-practice treatment (i.e., cold-water immersion and cool-first transport-second) (69.6% vs. 36.9%, χ2 = 8.480, p < 0.004, PR = 3.15, 95% CI = 1.38, 7.18). Conclusions: These findings demonstrate a lack of implementation of best-practice standards for EHS by EMS. Working with an athletic trainer appears to increase the likelihood of following best practices. Efforts should be made to improve EMS providers’ implementation of best-practice standards for the diagnosis and management of EHS to optimize patient outcomes.

Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).

BackgroundCoronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has caused extensive burden to individuals, families, countries, and the world. Effective treatments of COVID-19 are urgently needed.Methods and findingsThis is the first edition of a living systematic review of randomized clinical trials comparing the effects of all treatment interventions for participants in all age groups with COVID-19. We planned to conduct aggregate data meta-analyses, trial sequential analyses, network meta-analysis, and individual patient data meta-analyses. Our systematic review is based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) and Cochrane guidelines, and our 8-step procedure for better validation of clinical significance of meta-analysis results. We performed both fixed-effect and random-effects meta-analyses. Primary outcomes were all-cause mortality and serious adverse events. Secondary outcomes were admission to intensive care, mechanical ventilation, renal replacement therapy, quality of life, and nonserious adverse events. We used Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the certainty of evidence. We searched relevant databases and websites for published and unpublished trials until August 7, 2020. Two reviewers independently extracted data and assessed trial methodology.We included 33 randomized clinical trials enrolling a total of 13,312 participants. All trials were at overall high risk of bias. We identified one trial randomizing 6,425 participants to dexamethasone versus standard care. This trial showed evidence of a beneficial effect of dexamethasone on all-cause mortality (rate ratio 0.83; 95% confidence interval [CI] 0.75–0.93; p < 0.001; low certainty) and on mechanical ventilation (risk ratio [RR] 0.77; 95% CI 0.62–0.95; p = 0.021; low certainty). It was possible to perform meta-analysis of 10 comparisons. Meta-analysis showed no evidence of a difference between remdesivir versus placebo on all-cause mortality (RR 0.74; 95% CI 0.40–1.37; p = 0.34, I2 = 58%; 2 trials; very low certainty) or nonserious adverse events (RR 0.94; 95% CI 0.80–1.11; p = 0.48, I2 = 29%; 2 trials; low certainty). Meta-analysis showed evidence of a beneficial effect of remdesivir versus placebo on serious adverse events (RR 0.77; 95% CI 0.63–0.94; p = 0.009, I2 = 0%; 2 trials; very low certainty) mainly driven by respiratory failure in one trial.Meta-analyses and trial sequential analyses showed that we could exclude the possibility that hydroxychloroquine versus standard care reduced the risk of all-cause mortality (RR 1.07; 95% CI 0.97–1.19; p = 0.17; I2 = 0%; 7 trials; low certainty) and serious adverse events (RR 1.07; 95% CI 0.96–1.18; p = 0.21; I2 = 0%; 7 trials; low certainty) by 20% or more, and meta-analysis showed evidence of a harmful effect on nonserious adverse events (RR 2.40; 95% CI 2.01–2.87; p < 0.00001; I2 = 90%; 6 trials; very low certainty). Meta-analysis showed no evidence of a difference between lopinavir–ritonavir versus standard care on serious adverse events (RR 0.64; 95% CI 0.39–1.04; p = 0.07, I2 = 0%; 2 trials; very low certainty) or nonserious adverse events (RR 1.14; 95% CI 0.85–1.53; p = 0.38, I2 = 75%; 2 trials; very low certainty). Meta-analysis showed no evidence of a difference between convalescent plasma versus standard care on all-cause mortality (RR 0.60; 95% CI 0.33–1.10; p = 0.10, I2 = 0%; 2 trials; very low certainty). Five single trials showed statistically significant results but were underpowered to confirm or reject realistic intervention effects.None of the remaining trials showed evidence of a difference on our predefined outcomes. Because of the lack of relevant data, it was not possible to perform other meta-analyses, network meta-analysis, or individual patient data meta-analyses. The main limitation of this living review is the paucity of data currently available. Furthermore, the included trials were all at risks of systematic errors and random errors.ConclusionsOur results show that dexamethasone and remdesivir might be beneficial for COVID-19 patients, but the certainty of the evidence was low to very low, so more trials are needed. We can exclude the possibility of hydroxychloroquine versus standard care reducing the risk of death and serious adverse events by 20% or more. Otherwise, no evidence-based treatment for COVID-19 currently exists. This review will continuously inform best practice in treatment and clinical research of COVID-19.

Utilization of Outpatient and Intensive Treatment Services By Adults with Multiple Substance Use Disorders in the Medicaid Population

Research ObjectiveUse of multiple substances is common among adults who misuse opioids. Adverse consequences of drugs are more severe among multisubstance relative to single drug users. It is not known whether adults with multiple substance use disorders (multi‐SUD) including opioid use disorder (OUD) receive treatment at the same level compared with those with OUD only. If not, additional emphasis in interventions may be needed to target this population. This study sought to (1) assess whether adults with multi‐SUD are as likely to receive outpatient or intensive treatment compared with adults with OUD only and (2) determine whether any particular drug use combinations are at risk for not receiving treatment.Study DesignWe conducted a retrospective longitudinal study using IBM® MarketScan® Multi‐State Medicaid Database enrollment and claims data (2016‐2017). We used adjusted logistic regression to measure the association between clinical characteristics and receipt of treatment.Population StudiedThe sample included non‐Medicare‐eligible adults aged 18‐64 years who were continuously enrolled in Medicaid and had at least one claim in 2016 with a primary OUD diagnosis.Principal FindingsOf the 58,745 Medicaid enrollees with an initial OUD diagnosis in 2016, 29,478 had no other SUDs. The remaining 29,267 had additional SUD diagnoses. In the year following diagnosis, adults with multi‐SUD were less likely to receive OUD outpatient services or medication treatment than adults with OUD only (OR = 0.931, P = .0006). Adults with co‐occurring alcohol (OR = 0.774, P &lt; .0001), cannabis (OR = 0.848, P &lt; .0001), or stimulant (OR = 0.829, P &lt; .0001) disorder were significantly less likely to receive OUD outpatient treatment than adults with OUD only. Adults with a co‐occurring sedative, hypnotic, or anxiolytic use disorder (SHA) were the only group meaningfully more likely to receive OUD outpatient treatment (OR = 1.179, P &lt; .0001).Adults with multi‐SUD were more likely to use all types of higher intensity services than those with OUD only. Other than for detoxification services, individuals with OUD and a cocaine use disorder were most likely to experience all‐cause use of intensive treatment services. Individuals with OUD and alcohol use disorder were most likely to receive detoxification services (OR = 2.260, P &lt; .0001). Individuals with co‐occurring SHA and OUD used inpatient, emergency department, residential, and detoxification services more heavily compared with other multi‐SUD combinations.Only adults with co‐occurring SHA and OUD used outpatient mental health services and medication to a larger extent than those with OUD only. Those with OUD and a stimulant use disorder were significantly less likely to use such services (OR = 0.937, P = .0105).ConclusionsOur findings suggest that there are barriers to outpatient OUD and mental health treatment for adults with multi‐SUD. Adults with co‐occurring alcohol, cannabis, and stimulant misuse are particularly at risk for not receiving services. Adults with multi‐SUD receive more intensive services, which may reflect severity and lack of outpatient treatment before misuse escalation. Intensive services are expensive and should be provided along with outpatient OUD treatment to be most effective.Implications for Policy or PracticePrograms should account for barriers in connecting people with multi‐SUD to OUD treatment and implement best practices for treatment of non‐OUD SUDs.Primary Funding SourceSAMHSA.

Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities

ObjectiveRheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder with a global prevalence of approximately 0.5–1%. Patients with RA are at an increased risk of developing comorbidities (eg, cardiovascular disease,...